Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+)-amphetamine
reversible competitive inhibitor
(+/-)-6-hydroxytrypargine
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata, synthesized by reaction of 5-hydroxytryptamine hydrochloride with N-(3-[1,3]dioxolan-2-yl-propyl)-guanidine sulfate, overview
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
-
-
(1R,2R)-(-)-psi-ephedrine
-
IC50 for soluble enzyme: 5.03 mM, IC50 for immobilized enzyme: 88 mM, monoamine oxidase B; IC50 for soluble enzyme: 5.35 mM, IC50 for immobilized enzyme: 14.86 mM, monoamine oxidase A
(1S,2S)-(+)-psi-ephedrine
-
IC50 for soluble enzyme: 0.88 mM, IC50 for immobilized enzyme: 1.77 mM, monoamine oxidase A; IC50 for soluble enzyme: 10 mM, IC50 for immobilized enzyme: 234 mM, monoamine oxidase B
(1Z)-2-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.39
(2-methylprop-2-en-1-yl)hydrazine
-
(2-phenylprop-2-en-1-yl)hydrazine
-
(2E)-1,3-diphenylprop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methylphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-phenylprop-2-en-1-one
-
-
(2E)-1-(4-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one
competitive inhibition
(2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
competitive inhibition
(2E)-1-[4-(benzyloxy)phenyl]-3-(4-chlorophenyl)prop-2-en-1-one
-
-
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-(3-hydroxyphenyl)ethanamide
-
-
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-phenylethanamide
-
-
(2E)-2-[(1H-indol-3-yl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 10% inhibition; 0.1 mM, pH 7.4, 43% inhibition
-
(2E)-2-[(2-chloro-3-methoxyphenyl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 17% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carbothioamide
0.1 mM, pH 7.4, 32% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
-
-
(2E)-2-[1-(2,4,5-trifluorophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 23% inhibition
-
(2E)-2-[1-(2,4-dihydroxy-5-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 30% inhibition; 0.1 mM, pH 7.4, 8% inhibition
-
(2E)-2-[1-(4-chloro-3-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 13% inhibition; 0.3% inhibition
-
(2E)-2-[1-(4-iodophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 25% inhibition
-
(2E)-2-[1-[3-(dihydroxyamino)-4-methoxyphenyl]ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 19% inhibition; 0.1 mM, pH 7.4, 37.2% inhibition
-
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
-
-
(2E)-3-(2-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
-
(2E)-3-(3-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
-
inhibits MAO-A and MAO-B
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
-
-
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
-
-
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
-
(2E,4E)-5-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)penta-2,4-dienamide
i.e. guineensine, isolated from dried fruits of Piper longum, competitive inhibition; i.e. guineensine, isolated from dried fruits of Piper longum, competitive inhibition
(2E,4E,12E)-13-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)trideca-2,4,12-trienamide
i.e. methylpiperate, isolated from dried fruits of Piper longum, competitive inhibition; i.e. methylpiperate, isolated from dried fruits of Piper longum, competitive inhibition
(2R)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2R)-1-cyclohexyl-N-methyl-N-(1H-pyrrol-2-ylmethyl)propan-2-amine
-
(2S)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide
-
i.e. safinamide, a potent selective and reversible MAO-B inhibitor, occurs in two polymorphic forms. Both forms are orthorhombic and regarded as conformational polymorphs due to the differences in the orientation of the 3-fluorobenzyloxy and propanamide groups. Both structures pack with layers in the ac plane, structure overview
(3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
1% inhibition of isoform MAO-B at 0.01 mM, 14% inhibition of isoform MAO-A at 0.01 mM
(3E)-3-[2-(isopropylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
4% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-fluorobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate
-
6%inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate
-
13% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-chlorobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-nitrobenzenesulfonate
-
10% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 5-chlorothiophene-2-sulfonate
-
2% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
-
(3E)-7-hydroxy-3-[(4-methoxyphenyl)methylidene]-2,3-dihydro-4H-1-benzopyran-4-one
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
17% inhibition of isoform MAO-B at 0.01 mM
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(4-[[bis(methylene)(4-methylphenyl)-lambda6-sulfanyl]oxy]phenoxy)hydrazine
0.1 mM, complete inhibition
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(5E)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-(3-bromobenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-(4-chlorobenzylidene)-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(4-hydroxy-2,5-dimethoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(4-hydroxy-3-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-benzylidene-2-imino-1,3-thiazolidin-4-one
-
-
(5E)-5-benzylidene-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-[(3,5-dibromo-4-hydroxycyclohexa-1,4-dien-1-yl)methylidene]-1,3-thiazolidine-2,4-dione
-
-
(5R)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R,5'R)-3,3'-[1,4-diazepane-1,4-diylbis(3-fluorobenzene-4,1-diyl)]bis[5-(hydroxymethyl)-1,3-oxazolidin-2-one]
IC50: 0.001mM, at 0.15 mM kynuramine
(5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one
-
(5S)-5-(aminomethyl)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-1,3-oxazolidin-2-one
-
(5S)-5-(aminomethyl)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-1,3-oxazolidin-2-one
-
(5Z)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
L136468, binding mode, overview
(5Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
A6355
(5Z)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
L136662
(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
AS605240, binding mode, overview
(6-benzyloxy-2-naphthyl)-2-aminopropane
-
(6-butoxy-2-naphthyl)-2-aminopropane
-
(6-ethoxy-2-naphthyl)-2-aminopropane
-
(6-methoxy-2-naphthyl)-2-aminopropane
-
(6-methylthio-2-naphthyl)isopropylamine
-
(6-propoxy-2-naphthyl)-2-aminopropane
-
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
(aminomethyl)trimethylsilane
-
-
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine
-
-
(E)-3-(2-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(3,4-dimethoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(3-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-(diethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-(dimethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-chlorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-fluorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(10-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(5-(1,2,3,4-tetrahydroacridin-9-ylamino)pentyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(8-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(9-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methylbenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
(E)-5-(3-chlorostyryl)isatin
-
(E)-5-(3-fluorostyryl)isatin
-
(E)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(3,4,5-trimethoxybenzylidene)chroman-4-one
-
(E)-7-(6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(4-methoxybenzylidene)chroman-4-one
-
(E)-7-(8-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)3-(4-methoxybenzylidene)chroman-4-one
-
(E)-8-(2-furylethenyl)caffeine
-
-
(E)-8-(2-thienylethenyl)caffeine
-
-
(E)-8-(3,4-dichlorostyryl)caffeine
-
-
(E)-8-(3,5-ditrifluoromethylstyryl)caffeine
-
-
(E)-8-(3-bromostyryl)caffeine
-
-
(E)-8-(3-chlorostyryl)caffeine
(E)-8-(3-methylstyryl)caffeine
-
-
(E)-8-(3-trifluoromethylstyryl)caffeine
-
-
(E)-8-(4-chlorostyryl)caffeine
-
-
(E)-8-(4-fluorostyryl)caffeine
-
-
(E)-8-(4-methylstyryl)caffeine
-
-
(E)-8-(4-trifluoromethylstyryl)caffeine
-
-
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
-
-
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
-
-
(N-cyclopropyl-alpha-methylbenzylamine)
the inhibitor forms an adduct that allows reoxidation of the flavin on denaturation
(R)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
(R)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(R)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(R)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
(R)-amphetamine
-
IC50 for soluble enzyme: 0.0311 mM, IC50 for immobilized enzyme: 0.0991 mM, monoamine oxidase A; IC50 for soluble enzyme: 0.246 mM, IC50 for immobilized enzyme: 4.03 mM, monoamine oxidase B
(R)-N-(alpha-cyclohexylethyl),N-methyl-1H-pyrrole-2-carboxamide
-
(R)-N-(alpha-cyclohexylethyl)-1H-pyrrole-2-carboxamide
-
(R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
-
specific inhibitor of isoform MAO-B
(R,S)-amphetamine
-
IC50 for soluble enzyme: 0.0031 mM, IC50 for immobilized enzyme: 0.0244 mM, monoamine oxidase A; IC50 for soluble enzyme: 0.0625 mM, IC50 for immobilized enzyme: 3 mM, monoamine oxidase B
(S)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
(S)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(S)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(S)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
(S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)-benzo[d]isoxazol-3-yl]-oxazolidin-2-one
-
SL25.1188, inhibits MAO-B in the brain with 50% unspecific binding, overview
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo; i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
1,10 phenanthroline
-
weak inhibition
1,2,3,4-tetrahydroacridin-9-amine
-
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
1,3,7-trimethyl-8-[(E)-2-(3-thienyl)vinyl]-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3-dimethyl-5-nitro-1H-indazole
-
-
1,3-dimethyl-6-phenyl-1H-pteridine-2,4-dione
-
-
1,3-diphenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0098 mM, MAO-A; IC50: 0.2 mM, MAO-B
1,4-diphenyl-1,3-butadiene
1-(1-methylhydrazino)-3-(phenylthio)propan-2-ol
-
-
1-(1-methylhydrazino)-3-[methyl(phenyl)amino]propan-2-ol
-
-
1-(1-naphthyl)-2-aminopropane
-
1-(2-naphthyl)-2-aminopropane
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(octan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
-
-
1-(4-benzyloxyphenyl)-2-aminopropane
-
1-(4-butoxyphenyl)-2-aminopropane
-
1-(4-chlorobutyl)-5-nitro-1H-indazol-3-ol
-
-
1-(4-ethoxyphenyl)-2-aminopropane
-
1-(4-guanidinobutoxy)-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-(4-methoxy-phenyl)-2-aminopropane
-
1-(4-methylthiophenyl)-2-aminopropane
-
1-(4-propoxyphenyl)-2-aminopropane
-
1-(benzylideneamino)-3,4-dihydroquinolin-2(1H)-one
selective for MAO-B
1-(N-methylthiocarbamoyl)-3-(3-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(3-methylphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
1-acetyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000009 mM, MAO-A; IC50: 0.041 mM, MAO-B
1-acetyl-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00023 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(2,5-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0002 mM, MAO-A; IC50: 0.14 mM, MAO-B
1-acetyl-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00029 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(2-nitrophenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0003 mM, MAO-A; IC50: 0.09 mM, MAO-B
1-acetyl-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0001 mM, MAO-A; IC50: 0.088 mM, MAO-B
1-acetyl-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00024 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-bromophenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00001mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0002 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0001 mM, MAO-A; IC50: 0.02 mM, MAO-B
1-acetyl-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-5-(2,4-dimethoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.00001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-5-(2-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0001 mM, MAO-A; IC50: 0.038 mM, MAO-B
1-acetyl-5-(3,4-dimethoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.00001 mM, MAO-A; IC50: 0.025 mM, MAO-B
1-acetyl-5-(3-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000009 mM, MAO-A; IC50: 0.083 mM, MAO-B
1-acetyl-5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000008 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-amino-3,4-dihydroquinolin-2(1H)-one
selective for MAO-B
1-benzyl-5-nitro-1H-indazol-3-ol
-
-
1-guanidino-6-hydroxy-3,5-dihydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
-
-
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
-
-
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-3-(3-methylphenyl)pyrrole
-
-
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methyl-2-[(E)-2-(4-methylphenyl)vinyl]-1H-benzimidazole
-
-
1-methyl-2-[(E)-2-phenylvinyl]-1H-benzimidazole
-
-
1-methyl-2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-1H-benzimidazole
-
-
1-methyl-3-(3-bromophenyl)pyrrole
-
-
1-methyl-3-(3-chlorophenyl)pyrrole
-
-
1-methyl-3-(3-fluorophenyl)pyrrole
-
-
1-methyl-3-(3-methylphenyl)-1H-pyrrole
-
-
1-methyl-3-(3-methylphenyl)pyrrole
-
-
1-methyl-3-(3-trifluoromethylphenyl)pyrrole
-
-
1-methyl-3-(4-methylphenyl)-1H-pyrrole
-
-
1-methyl-3-phenyl-1H-pyrrole
-
-
1-methyl-3-phenylpyrrole
-
-
1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrrole
-
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
-
1-methyl-4-phenylpyridinium
-
1-methyl-5-nitro-1H-indazol-3-ol
-
inhibits MAO-B by 34% at 0.015 mM
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
-
1-N-allylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-allylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor; non-selective inhibitor
1-N-ethylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-ethylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor; non-selective inhibitor
1-N-methylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-methylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor; non-selective inhibitor
1-N-phenylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-phenylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor; non-selective inhibitor
1-O-n-octyl-beta-D-glucopyranoside
-
at concentrations well below the critical micelle concentration
1-phenyl-2-aminopropane
-
1-phenyl-N-(1H-pyrrol-2-ylmethyl)methanamine
-
1-phenylcyclopropylamine
the inhibitor forms an irreversible flavin adduct
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-[3,5-bis(ethylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
1-[3,5-bis(tert-butylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
1-[3-(4-chlorophenoxy)-2-methoxypropyl]-1-methylhydrazine
-
-
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
-
11H-indolo[3,2-c]cinnoline
29% inhibition at 0.05 mM
2,2'-bipyridyl
-
50% inhibition at 1 mM
2,2'-dipyridyl disulfide
-
-
2,2-dibutyl-3-acetyl-5-(3,5-dimethylphenyl)-1,3,4-oxadiazoline
-
0.8 mM, 42.8% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,3,5-trifluoro-4-methoxybenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 82% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamid
-
1 mM, 72% inhibition
2,2-dibutyl-5-(4-chlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 59% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(furan-2-yl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 73% inhibition
2,4-dichloro-N'-(nonan-5-yl)benzohydrazide
-
-
2,4-dichlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.92
2,4-dichlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.03
2,4-dimethoxy-5-hydroxybenzaldehyde
IC50: 0.042 mM, monoamine oxidase A; IC50: 0.39 mM
2,6-dimethoxyphenol
IC50: 0.0624 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
2-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
IC50: 0.0001 mM, MAO-A; IC50: 0.019 mM, MAO-B
2-(1-acetyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
IC50: 0.001 mM, MAO-A; IC50: 0.07 mM, MAO-B
2-(1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
IC50: 0.000072 mM, MAO-A; IC50: 0.04 mM, MAO-B
2-(2,4-dichlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(3-hydroxyphenyl)acetamide
6164872
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-phenylacetamide
6163851
2-(2-benzofuranyl)-2-imidazoline
at micromolar concentrations, to a site distinct from the active site on at least two forms of the pure enzyme, probably corresponding to oxidised and reduced enzyme states
2-(2-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-ethoxylpyridin-3-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3,4,5-trimethoxyphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3,5-dimethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3-methylphenyl)-4-(butoxycarbonylethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3-nitrophenyl)-9H-indeno[2,1-d]pyrimidin-9-one
12% inhibition at 0.001 mM; 5% inhition at 0.001 mM
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
2-(4'-butoxyphenyl)thiomorpholin-5-one
2-(4'-butoxyphenyl)thiomorpholine oxalate
2-(4'-ethoxyphenyl)thiomorpholin-5-one
2-(4'-ethoxyphenyl)thiomorpholine oxalate
2-(4'-methoxyphenyl)thiomorpholin-5-one
2-(4'-methoxyphenyl)thiomorpholine oxalate
2-(4'-propoxyphenyl)thiomorpholin-5-one
2-(4'-propoxyphenyl)thiomorpholine oxalate
2-(4,5-dihydroimidazol-2-yl)-isoquinoline
reversible non-competitive/mixed inhibitor
2-(4,5-dihydroimidazol-2-yl)-quinoline
reversible non-competitive/mixed inhibitor
2-(4-bromophenyl)cyclopropanamine
-
2-(4-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-chlorophenyl)-N-cyclohexyl-2-(3-ethynyl-2-oxo-4-phenylquinolin-1(2H)-yl)acetamide
selective for MAO-B
2-(4-ethylphenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-ethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-fluorophenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-methoxyphenyl)cyclopropanamine
-
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
-
-
2-(5,7-dibromobenzofuran-2-yl)-imidazoline
reversible non-competitive/mixed inhibitor
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
-
-
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
-
2-(aminooxy)-1-phenylethanol
-
2-(benzo[d][1,3]dioxol-5-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
-
-
2-(naphthalen-1-yl)cyclopropanamine
-
2-(naphthalen-2-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(thiophen-3-yl)cyclopropanamine
-
2-bromo-N-(2-morpholinoethyl)nicotinamide
-
2-bromo-N-(3-morpholinopropyl)nicotinamide
-
2-Bromoethylamine
-
complete inhibition at 0.01 mM
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
-
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
-
2-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
2-chloro-N-(2-morpholinoethyl)nicotinamide
-
2-chloro-N-(3-morpholinopropyl)nicotinamide
-
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-ethoxy-N'-(nonan-5-yl)nicotinohydrazide
-
-
2-ethylaminobenzylamine dihydrochloride
-
2-hydrazinyl-4-(3-nitrophenyl)-1,3-thiazole
0.1 mM, pH 7.4, 10% inhibition; 0.1 mM, pH 7.4, 6% inhibition
-
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
2-hydroxyquinoline
-
reversible by dialysis
2-methoxyphenol
IC50: 0.175 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
2-methyl-5-methylaniline
IC50: 0.15 mM, monoamine oxidase A; IC50: above 0.5 mM
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
-
2-methylaminobenzylamine dihydrochloride
-
2-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.45
2-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.18
2-oxo-2H-chromen-7-yl benzenesulfonate
-
2-oxo-N-(2,3,5,6-tetrafluoropyridin-4-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(pentafluorophenyl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(propan-2-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-[3-(trifluoromethyl)phenyl]-2H-chromene-3-carboxamide
-
-
2-oxo-N-[4-(propan-2-yl)phenyl]-2H-chromene-3-carboxamide
-
-
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
46% inhibition at 0.05 mM
2-phenyl-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-phenyl-5H-indeno[1,2-d]pyrimidine
37% inhibition at 0.02 mM
2-phenyl-9H-indeno[2,1-d]pyrimidine
-
2-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
2-Phenylethylamine
time-dependent, slowly reversible suicide inhibition. Addition of 2-phenylethylamine (10mM) to the enzyme results in immediate bleaching of the absorbance peak at 460 nm, a consequence of rapid reduction of the flavin cofactor by 2-phenylethylamine at steady state
2-phenylthiomorpholin-5-one
2-phenylthiomorpholine oxalate
2-[(1E,3E)-4-(3-chlorophenyl)buta-1,3-dien-1-yl]-3,5,7-trimethyl-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
-
-
2-[(E)-2-(4-bromophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-chlorophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-fluorophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-methoxyphenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[1-(4-chlorophenyl)-5-(2,3-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.008 mM, MAO-A; IC50: 0.3 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.009 mM, MAO-A; IC50: 0.3 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0094 mM, MAO-A; IC50: 0.48 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.025 mM, MAO-B; IC50: 0.097 mM, MAO-A
2-[1-(4-chlorophenyl)-5-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.098 mM, MAO-A; IC50: 2.0 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.013 mM, MAO-A; IC50: 3.8 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.09 mM, MAO-A; IC50: 1.0 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.094 mM, MAO-A; IC50: 1.8 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.088 mM, MAO-A; IC50: 0.2 mM, MAO-B
2-[1-(4-chlorophenyl)-5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0095 mM, MAO-A
2-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0000086 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.00001 mM, MAO-A; IC50: 0.0001 mM, MAO-B
2-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.000008 mM, MAO-A; IC50: 0.019 mM, MAO-B
2-[1-acetyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0001 mM, MAO-A; IC50: 0.04 mM, MAO-B
2-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000028 mM, MAO-A; IC50: 0.00006 mM, MAO-B
2-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.000009 mM, MAO-A; IC50: 0.0072 mM, MAO-B
2-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.002 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0000088 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.0001 mM, MAO-A; IC50: 0.06 mM, MAO-B
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
2-[4-(trifluoromethyl)phenyl]cyclopropanamine
-
2-[5-(3-bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.089 mM, MAO-A; IC50: 0.25 mM, MAO-B
2-[5-(4-bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.12 mM, MAO-A; IC50: 1 mM, MAO-B
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
-
-
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
-
-
2-{1-(4-chlorophenyl)-5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-3-yl}phenol
IC50: 0.4 mM, MAO-B
2-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride
-
3,4,5-trimethoxy-N'-(nonan-5-yl)benzohydrazide
-
-
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
-
-
3,4-dimethoxyaniline
IC50: 0.131 mM, monoamine oxidase A
3,4-dimethoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.88
3,4-dimethoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.52
3,4-dimethyl-2-oxo-2H-chromen-7-yl 4-methoxybenzenesulfonate
-
3,4-dimethyl-2-oxo-2H-chromen-7-yl benzenesulfonate
-
3,4-dimethyl-7-(2-oxo-2-phenylethoxy)-2H-chromen-2-one
-
3,4-dimethyl-7-(2-phenoxyethoxy)-2H-chromen-2-one
pIC50 for MAO-A: 4.99; pIC50 for MAO-B: 7.57
3,4-dimethyl-7-(2-phenylethyl)-2H-chromen-2-one
pIC50 for MAO-A: 5.15; pIC50 for MAO-B: 6.34
3,4-dimethyl-7-phenoxy-2H-chromen-2-one
pIC50 for MAO-A: 4.5; pIC50 for MAO-B: 5.49
3,4-dimethyl-7-[(3-nitrobenzyl)oxy]-2H-chromen-2-one
-
3,4-dimethyl-7-[(pentafluorobenzyl)oxy]-2H-chromen-2-one
-
3,4-dimethyl-7-{[3-(trifluoromethoxy)benzyl]oxy}-2H-chromen-2-one
-
3,5,7-trimethyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
3,5-bis(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3,5-di-2-thienyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
-
-
3,5-dimethyl-N'-(nonan-5-yl)benzohydrazide
-
-
3,5-diphenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-(2,4-dimethoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0018 mM, MAO-A; IC50: 0.04 mM, MAO-B
3-(2-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.01 mM, MAO-A; IC50: 0.5 mM, MAO-B
3-(2-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
3-(2-naphthyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
3-(3,4-dimethoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.003 mM, MAO-A; IC50: 0.017 mM, MAO-B
3-(3-aminophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
12% inhibition at 0.01 mM; 17% inhibition at 0.01 mM
3-(3-bromophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-chlorophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-fluorophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-fluorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-methoxyphenyl)-1-methyl-1H-pyrrole
-
-
3-(3-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000014 mM, MAO-A; IC50: 0.001 mM, MAO-B
3-(3-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-methylphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.09 mM, MAO-A; IC50: 0.98 mM, MAO-B
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
3% inhibition at 0.01 mM
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
23% inhibition at 0.01 mM
3-(3-tert-butylphenyl)-1-methyl-1H-pyrrole
-
-
3-(4-bromophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-bromophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0074 mM, MAO-A; IC50: 0.087 mM, MAO-B
3-(4-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-chlorophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0099 mM, MAO-A; IC50: 0.1 mM, MAO-B
3-(4-chlorophenyl)-5-(4-fluorocyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-chlorophenyl)-5-(4-methoxycyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-chlorophenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-chlorophenyl)-5-cyclohexa-1,5-dien-1-yl-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-fluorophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-fluorophenyl)-5-(2-furyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-acetylaminophenyl)-N-phenyl-4,5-dihydro-1H -pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-acetylaminophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxycyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-hydroxyphenyl)-2-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoic acid
-
-
3-(4-hydroxyphenyl)propionic acid
-
-
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
-
-
3-(4-methoxybenzyl)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
3-(4-methoxyphenyl)-1-methyl-1H-pyrrole
-
-
3-(4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.00011 mM, MAO-A; IC50: 0.0125 mM, MAO-B
3-(4-methoxyphenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-methylphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0069 mM, MAO-A; IC50: 0.05 mM, MAO-B
3-(4-nitrophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000086 mM, MAO-A; IC50: 0.00145 mM, MAO-B
3-(4-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(5-oxo-5H-indeno[1,2-c]pyridazin-3-yl)benzonitrile
-
3-(benzyloxy)-5-nitro-1H-indazole
-
-
3-(benzyloxy)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(benzyloxy)-6a,10a-dihydro-6H-benzo[c]chromen-6-one
-
3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-amino-4-aminomethylpyridine dihydrochloride
-
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
-
-
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-benzyl-5-nitro-1H-indazole
-
-
3-benzyl-5H-indeno[1,2-c]pyridazin-5-one
-
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
3-hydroxyphenylacetic acid
-
-
3-methoxy-1-methyl-5-nitro-1H-indazole
-
inhibits MAO-B by 52% at 0.015 mM
3-methoxy-5-nitro-1H-indazole
-
-
3-methoxyphenol
IC50: 0.024 mM, monoamine oxidase A
3-methyl-5-nitro-1H-indazole
-
-
3-methyl-8-(4,4,4-trifluoro-butoxy)indeno[1.2-c]pyridazin-5-one
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
3-methylamino-4-aminomethylpyridine dihydrochloride
-
3-oxo-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
3-phenyl-4-(phenylseleno)isoquinoline
reversibly inhibits isoform MAO-B activity
3-phenyl-4-(phenylthio)isoquinoline
-
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
21% inhibition at 0.01 mM
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
-
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
12% inhibition at 0.01 mM
3-[(5E)-5-benzylidene-2,4-dioxo-1,3-thiazolidin-3-yl]propanenitrile
-
-
3-[(5E)-5-benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
R598127
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
-
-
3-[(E)-2-phenylvinyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-[2-(ethylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
17% inhibition of isoform MAO-A at 0.01 mM
3-[2-(methylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
31% inhibition of isoform MAO-A at 0.01 mM
3-[4-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-[[4-(trifluoromethyl)phenoxy]methyl]-5H-indeno[1,2-c]pyridazin-5-one
48% inhibition at 0.01 mM
3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
4,4'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dibutan-1-ol dihydrochloride
-
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,2,3-triol
IC50: 0.0001 mM, MAO-A; IC50: 0.39 mM, MAO-B
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
IC50: 0.0001 mM, MAO-A; IC50: 0.08 mM, MAO-B
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
IC50: 0.00005 mM, MAO-A; IC50: 0.062 mM, MAO-B
4-(1-acetyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
IC50: 0.0001 mM, MAO-A; IC50: 0.03 mM, MAO-B
4-(1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
IC50: 0.000073 mM, MAO-A; IC50: 0.003 mM, MAO-B
4-(2,4-dichlorophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 25% inhibition; 0.1 mM, pH 7.4, 31% inhibition
-
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-(2-bromophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 24% inhibition
-
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
-
-
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenylseleno)-3-phenylisoquinoline
-
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
-
-
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
-
4-([6-[(4-cyanophenyl)methoxy]-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
-
-
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
-
-
4-benzyl-1-cyclopropyl-1,2,3,6-tetrahydropyridine
-
-
4-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
4-chloro-N-(2-morpholinoethyl)nicotinamide
-
4-chloro-N-(3-morpholinopropyl)nicotinamide
-
4-chlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.42
4-chlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.0
4-ethyl-N'-(nonan-5-yl)benzohydrazide
-
-
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
IC50: 0.0089 mM, monoamine oxidase B; IC50: 0.0134 mM, monoamine oxidase A
4-Hydroxy-3-methoxybenzylamine
IC50: 0.13 mM, monoamine oxidase A; IC50: 0.382 mM, monoamine oxidase B
4-hydroxy-3-methoxyphenethyl alcohol
IC50: 0.18 mM, monoamine oxidase A
4-hydroxy-3-methoxyphenyl acetone
IC50: 0.0302 mM, monoamine oxidase A
4-hydroxyphenylacetic acid
-
-
4-methoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.72
4-methoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.3
4-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 6.69
4-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.67
4-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.0
4-oxo-4H-chromene-3-carboxylic acid
-
specific for MAO-B
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
-
4-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenyl methanesulfinate
-
-
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
-
-
4-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
-
-
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
-
-
4-[(methylamino)carbonyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
9% inhibition of isoform MAO-B at 0.01 mM, 8% inhibition of isoform MAO-A at 0.01 mM
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-[1-(cyclopropylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[1-(ethylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.0001 mM, MAO-A; IC50: 0.038 mM, MAO-B
4-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.00001 mM, MAO-A; IC50: 0.02 mM, MAO-B
4-[1-acetyl-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0000086 mM, MAO-A; IC50: 0.087 mM, MAO-B
4-[1-acetyl-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000008 mM, MAO-A; IC50: 0.13 mM, MAO-B
4-[1-acetyl-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0000088 mM, MAO-A; IC50: 0.1 mM, MAO-B
4-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.00001 mM, MAO-A; IC50: 0.00002 mM, MAO-B
4-[1-acetyl-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.00001 mM, MAO-A; IC50: 0.023 mM, MAO-B
4-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000013 mM, MAO-A; IC50: 0.000038 mM, MAO-B
4-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.000008 mM, MAO-A; IC50: 0.019 mM, MAO-B
4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.00001 mM, MAO-A; IC50: 0.12mM, MAO-B
4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0001 mM, MAO-A; IC50: 0.04 mM, MAO-B
4-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000009 mM, MAO-A; IC50: 0.083 mM, MAO-B
4-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.000009 mM, MAO-A; IC50: 0.0072 mM, MAO-B
4-[1-acetyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000009 mM, MAO-A; IC50: 0.042 mM, MAO-B
4-[1-acetyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0001mM, MAO-A; IC50: 0.03 mM, MAO-B
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[4-(benzyloxy)phenoxy]hydrazino]butanenitrile
0.1 mM, 39% inhibition
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[[(4-oxo-3,4-dihydroquinazolin-6-yl)oxy]methyl]benzonitrile
-
-
4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoic acid
-
-
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
-
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
-
5,7-diethyl-3-methyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
5-(2-furyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(2-furyl)-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl)-1,3-thiazolidine-2,4-dione
i.e. rosiglitazone
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-chlorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorophenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-fluorophenyl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-hydroxy-3,5-dimethylbenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methylcyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methylcyclohexa-1,5-dien-1-yl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methylphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-[(1-methylcyclohexyl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. ciglitazone
5-(4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. troglitazone
5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. pioglitazone, docking of R-pioglitazone in the substrate cavity of MAO-B
5-(aminomethyl)-3-aryl-2-oxazolidinones
-
-
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2-chlorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
5-bromo-N-(2-morpholinoethyl)nicotinamide
-
5-bromo-N-(3-morpholinopropyl)nicotinamide
-
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
-
-
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
5-cyclohexa-1,5-dien-1-yl-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-cyclohexa-1,5-dien-1-yl-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-cyclohexa-1,5-dien-1-yl-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-fluoro-alpha-methyltryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
5-fluorotryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
5-nitro-1-(pyridin-2-ylmethyl)-1H-indazol-3-ol
-
-
5-nitroindazole
-
inhibits MAO-B by 98.5% at 0.015 mM
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-1,3-thiazolidine-2,4-dione ammoniate (1:1)
-
-
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-2-imino-1,3-thiazolidin-4-one
-
-
6,11-dihydro-5H-benzo[a]carbazole
38% inhibition at 0.025 mM
6-(3-chlorophenyl)-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
6-amino-1,3-dimethyl-5-([1-phenylmeth-(E)-ylidene]-amino)-1H-pyrimidine-2,4-dione
-
-
6-amino-1,3-dimethyl-5-[(E)-3-phenyl-prop-2-en-(E)-ylideneamino]-1H-pyrimidine-2,4-dione
-
-
6-amino-5-([1-(3-chlorophenyl)-meth-(E)-ylidene]-amino)-1,3-dimethyl-1H-pyrimidine-2,4-dione
-
-
6-amino-5-[(E)-3-(3-chloro-phenyl)-prop-2-en-(E)-ylideneamino]-1,3-dimethyl-1H-pyrimidine-2,4-dione
-
-
6-chloro-N-(2-morpholinoethyl)nicotinamide
-
6-chloro-N-(3-morpholinopropyl)nicotinamide
-
6-fluoro-alpha-methyltryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
6-fluoro-N-(2-morpholinoethyl)nicotinamide
-
6-fluoro-N-(3-morpholinopropyl)nicotinamide
-
6-fluorotryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
6-hydroxy-N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
6-methyl-N-(2-morpholinoethyl)nicotinamide
-
6-methyl-N-(3-morpholinopropyl)nicotinamide
-
6-nitroindazole
-
inhibits MAO-B by 89% at 0.015 mM, also inhibits MAO-A
6-[(3-iodophenyl)methoxy]-3-[(3-iodophenyl)methyl]quinazolin-4(3H)-one
-
-
6-[(3-iodophenyl)methoxy]quinazolin-4(3H)-one
-
-
6-[(4-fluorophenyl)methoxy]-3-[(4-fluorophenyl)methyl]quinazolin-4(3H)-one
-
-
6-[(E)-2-(3-chloro-phenyl)-vinyl]-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
6-[(E)-2-(3-chlorostyryl)]-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-(2-hydroxy-2-phenylethyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(3-chlorobenzyloxy)-3-methyl-2H-chromen-2-one
pIC50 for MAO-A: 4.9; pIC50 for MAO-B: 8.29
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(3-chlorobenzyloxy)-4-formylcoumarin
-
-
7-(3-phenylprop-2-en-1-yloxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 4.5; pIC50 for MAO-B: 6.95
7-(anilinomethyl)-2H-chromen-2-one
-
7-(benzenesulfonylmethoxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 5.55; pIC50 for MAO-B: 6.06
7-(benzylamino)-3,4-dimethyl-2H-chromen-2-one
-
7-(benzyloxy)-2H-chromen-2-one
-
7-(benzyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(benzyloxy)-4-methyl-2H-chromen-2-one
-
7-(benzyloxy)-4-phenyl-2H-chromen-2-one
-
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
-
-
7-benzenesulfonyloxy-2H-chromen-2-one
pIC50 for MAO-A: 6.35; pIC50 for MAO-B: 4.26
7-benzyloxy-3-methyl-2H-chromen-2-one
pIC50 for MAO-A: 5.26; pIC50 for MAO-B: 8.18
7-benzylsulfonyl-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 4.73; pIC50 for MAO-B: 5.56
7-benzylthio-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 5.0; pIC50 for MAO-B: 7.4
7-nitroindazole
-
inhibits MAO-B by 35% at 0.015 mM
7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
-
-
7-[(3-chlorophenyl)methoxy]-4-(methylaminomethyl)chromen-2-one
-
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
8-(-3-chlorostyryl)-caffeine
by means of its dual action as A2A antagonist and MAO-B inhibitor 8-(-3-chlorostyryl)-caffeine reverses behavior and biochemical alterations, observed in the 6-OHDA-lesioned rats, pointing out to its potential benefit for the treatment of Parkinson's disease
8-(3-chloro)styrylcaffeine
-
-
8-(3-chlorostrylyl)caffeine
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
8-(3-chlorostyryl)-caffeine
-
-
8-(3-chlorostyryl)caffeine
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
8-hydroxyquinoline
-
reversible by the addition of Zn2+, Ni2+, Co2+
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
9,11-dimethylpurino[7,8-c]quinazoline-8,10(9H,11H)-dione
-
-
Acetylcholine
competitively inhibits monoamine oxidase A in the brain in a tissue-dependent manner, inhibition of MAO-A in cerebellum; competitively inhibits monoamine oxidase B in the brain in a tissue-dependent manner, inhibition of MAO-B in basal ganglia
Acriflavin
-
irreversible inhibitor
aminoguanidine
-
complete impairment of SSAO activity produced by aminoguanidine-treatment in obese rats is likely responsible for a weak limitation of fat deposition. Aminoguanidine may be useful for treating obesity via its SSAO blocking properties
amitriptyline
competive inhibition with 2-phenylethylamine as substrate
befloxatone
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site
benzaldehyde
-
strong competitive inhibitor
benzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 8.14
benzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 5.92
benzhydrylidene-prop-2-ynyl-amine
-
-
benzoic acid (2H-2-oxochromen-7-yl)methyl ester
pIC50 for MAO-A: 5.02; pIC50 for MAO-B: 5.62
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
benzyl cyanide
-
reversible inhibitor
benzylhydrazine
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview; the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
beta-carbolines
-
competitive reversible and potent inhibitor
beta-phenylethylidenehydrazine
a neuroprotective drug, inhibits MAO-A by 26.7%; a neuroprotective drug, inhibits MAO-B by 14.9%
CdSO4
-
1 mM, 10% inhibition, monoamine oxidase B; 1 mM, 90% inhibition with serotonin as substrate, monoamine oxidase A
cinnamyl alcohol
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
cis-2,4,5-trimethoxypropenylbenzene
IC50: 0.142 mM, monoamine oxidase A; IC50: 0.362 mM, monoamine oxidase B
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
cis-N-benzyl-2-methoxycyclopropylamine
high inhibitory action, exhibits a poor isozyme selectivity; high inhibitory action, exhibits a poor isozyme selectivity
-
CuSO4
-
1 mM, 95% inhibition with serotonin as substrate, monoamine oxidase A
cyanidin
-
competitive interaction of cyanidin with MAO A plus a mixed competitive and non-competitive mode of interaction of cyanidin with MAO B
cyanidin-3,5-diglucoside
-
-
cyanidin-3-O-beta-D-galactoside
-
-
cyanidin-3-O-beta-D-glucoside
-
mixed competitive and non-competitive mode of interaction with both enzyme isozymes
cyanidin-3-O-beta-D-rutinoside
-
-
cyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.69
cyclopentanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 6.85
dehydroepiandrosterone
at 0.1 mM, inhibition of MAO-A by 44.2%; at 0.1 mM, inhibition of MAO-B by 61.2%
delphinidin-3-O-beta-D-glucoside
-
-
di(2-hydroxyethyl)methyldodecylammonium
reversible competitive inhibitor
di(2-hydroxyethyl)methyldodecylammonium ion
-
a biocide, inhibits MAO-B
epigallocatechin gallate dimer
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
esuprone
-
inhibits MAO-A reversibly
ethyl 4-hydroxy-3-methoxycinnamate
IC50: 0.0057 mM, monoamine oxidase B; IC50: 0.0247 mM, monoamine oxidase A
ethyl 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoate
-
-
ethyl-4-hydroxy-3-methoxyphenylacetate
IC50: 0.081 mM, monoamine oxidase A
eugenol
IC50: 0.0344 mM, monoamine oxidase A; IC50: 0.288 mM, monoamine oxidase B
eugenol methyl ether
IC50: 0.11 mM, monoamine oxidase A; IC50: 0.269 mM, monoamine oxidase B
harmalol
-
identification by HPLC-ESI-mass spectrometry
harmol
-
identification by HPLC-ESI-mass spectrometry
indol -2,3-dione
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
isoproniazid
-
inhibits MAO-A and MAO-B irreversibly
lamotrigine
its in vivo MAO-B inhibiting effect might contribute in part to its antidepressant activity
LU-53439
-
inhibits MAO-B reversibly
malvidin 3-O,5-O-di-beta-D-glucoside
-
-
malvidin-3-O-beta-D-galactoside
-
-
malvidin-3-O-beta-D-glucoside
-
-
Mesobuthus gibbosus venom peptide
-
with specific MAO-A inhibitory activity, reversible, non-competitive, may be responsible for the anxiogenic effects of the scorpion venom on animals and humans
-
metamphetamine
i.e. N-methyl-1-phenyl-2-propanamine; i.e. N-methyl-1-phenyl-2-propanamine
-
metanephrine
IC50: 0.252 mM, monoamine oxidase A
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
-
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
-
-
N'-(2-cyanoethyl)-4-ethylbenzohydrazide
-
-
N'-(nonan-5-yl)-2-naphthohydrazide
-
-
N'-(nonan-5-yl)benzo[d][1,3]dioxole-5-carbohydrazide
-
-
N'-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carbohydrazide
-
-
N,1-dimethyl-N-prop-2-yn-1-yl-1H-pyrrole-2-carboxamide
-
N,N'-(1R,2S)-cyclohexane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
N,N'-1,2-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
N,N'-1,4-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
N,N'-bis[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]butanediamide
IC50: 0.09 mM, at 0.15 mM kynuramine
N,N'-butane-1,4-diylbis(2-oxo-2H-chromene-3-carboxamide)
N,N'-butane-1,4-diylbis(7-methoxy-2-oxo-2H-chromene-3-carboxamide)
N,N'-ethane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
N,N'-hexane-1,6-diylbis(2-oxo-2H-chromene-3-carboxamide)
N,N'-[(1,5-dioxopentane-1,5-diyl)bis[piperazine-4,1-diyl(3-fluorobenzene-4,1-diyl)[(5R)-2-oxo-1,3-oxazolidine-3,5-diyl]methanediyl]]diacetamide
IC50: 0.0005 mM, at 0.15 mM kynuramine
N-((4-isopropylphenyl)-2-oxo-2H-chromene-3-carboxamide)-amide
-
-
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-3-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
i.e. ParSL-3, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-A
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-4-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
i.e. ParSL-2, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-B
N-(1-phenylethyl)-1H-pyrrole-2-carboxamide
-
N-(1H-pyrrol-2-ylmethyl)prop-2-yn-1-amine
-
N-(2,3-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-difluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-4-chlorobenzamide
-
N-(2-aminoethyl)-aryl-carboxamide
-
N-(2-aminoethyl)-p-chlorobenzamide
N-(2-benzylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-chloro-6-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-cyclohexylethyl)-N-methyl-1H-pyrrole-2-carboxamide
-
N-(2-methyl-1H-indol-5-yl)benzamide
-
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
-
N-(2-methyl-6-chlorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-methyl-6-chlorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-morpholinoethyl)nicotinamide
-
N-(2-phenylethyl),N-methyl-1H-pyrrole-2-carboxamide
-
N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3'-fluorophenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
N-(3,4-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-8-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-8-methyl-2-oxo-7-(2-phenylethyl)-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethyl-2-oxo-2H-chromen-7-yl)benzamide
-
N-(3,4-dimethyl-2H-2-oxochromen-7-yl)-N,4-dimethylbenzensulfonamide
pIC50 for MAO-A: 5.34; pIC50 for MAO-B: 4.5
N-(3,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
N-(3-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-morpholinopropyl)nicotinamide
-
N-(3-phenylpropyl),N-methyl-1H-pyrrole-2-carboxamide
-
N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide
-
N-(3-trifluoromethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}phenyl)acetamide
-
N-(4-benzyloxybenzyl)-4-methylthioamphetamine
-
N-(4-butoxybenzyl)-4-methylthioamphetamine
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-hydroxybenzyl)-4-methylthioamphetamine
weak inhibition of MAO-A; weak inhibition of MAO-B
N-(4-isopropylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-isopropylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methanesulfonylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methoxybenzyl)-4-methylthioamphetamine
-
N-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-phenylbutyl),N-methyl 1H-pyrrole-2-carboxamide
-
N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide
-
N-(biphenyl-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(butan-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(cycloheptylidenemethyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-amine
-
-
N-(prop-2-ynyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-([(5S)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
N-([(5S)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
N-2-phenylethyl-1H-pyrrole-2-carboxamide
-
N-benzyl,N-methyl-1H-pyrrole-2-carboxamide
-
N-benzyl-(4-methylthioamphetamine)
weak inhibition of MAO-A; weak inhibition of MAO-B
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine
most selective MAO-A inhibitor
N-benzyl-12-isothiocyanato-N-methyldodecan-1-amine
irreversible inhibition with respect to isoform MAO-A, competitive inhibition with respect to isoform MAO-B; irreversible inhibition with respect to isoform MAO-A, competitive inhibition with respect to isoform MAO-B
N-benzyl-1H-pyrrole-2-carboxamide
-
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine
-
N-benzyl-N-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methylprop-2-yn-1-amine
-
i.e. pargyline
N-benzylprop-2-yn-1-amine
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-cyclohexyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-isobutyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-isopropyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methoxy-2-(3-methylphenyl)maleimide
-
-
N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine
pH 7.4, 38°Cmost selective MAO-B inhibitor
N-methyl-1-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
N-methyl-2-(3-bromophenyl)maleimide
-
-
N-methyl-2-(3-chlorophenyl)maleimide
-
-
N-methyl-2-(3-fluorophenyl)maleimide
-
-
N-methyl-2-(3-methylphenyl)maleimide
-
-
N-methyl-2-(3-trifluoromethylphenyl)maleimide
-
-
N-methyl-2-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
N-methyl-2-phenylmaleimide
-
-
N-methyl-3-phenyl-N-(1H-pyrrol-2-ylmethyl)propan-1-amine
-
N-methyl-4-phenyl-N-(1H-pyrrol-2-ylmethyl)butan-1-amine
-
N-methyl-N-(1-phenylethyl)-1H-pyrrole-2-carboxamide
-
N-methyl-N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-methyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]prop-2-yn-1-amine
-
N-phenyl-1H-indazole-5-carboxamide
N-phenyl-1H-pyrrole-2-carboxamide
-
N-prop-2-yn-1-yl-1H-pyrrole-2-carboxamide
-
N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-propargyl-l(R)-aminoindan
i.e. rasagiline. N-Propargyl-l(R)-aminoindan is well tolerated and effective in the treatment of early Parkinson's disease and as adjunctive treatment in levodopa-treated patients with Parkinson's disease experiencing motor fluctuations
N-[(1R)-1-cyclohexylethyl]-1H-pyrrole-2-carboxamide
-
N-[(1S)-1-cyclohexylethyl]-1H-pyrrole-2-carboxamide
-
N-[3-(2,4-dichlorophenoxy)propyl]-N-methyl-prop-2-yn-1-amine
-
i.e. clorgiline
N-[4-(methylsulfonyl)phenyl]-2-oxo-2H-chromene-3-carboxamide
-
-
N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
-
N1,N12-dibenzyldodecane-1,12-diamine
-
N1-(3-aminopropyl)-N4-(3-((naphthalen-2-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((pyridin-3-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((thiophen-2-ylmethyl)amino)propyl)butane-1,4-diamine
mixed-type reversible inhibition with respect to isoform MAO-A and MAO-B; mixed-type reversible inhibition with respect to isoform MAO-A and MAO-B
naringenin
the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions; the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions
NW 1772
-
specific inhibitor of isoform MAO-B
o-eugenol
IC50: 0.101 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
oleamide
-
inhibits MAO B
p-(propylthio)-phenylisopropylamine
-
p-nitrobenzylamine
substrate for wild-type enzyme, competitive inhibitor for mutant enzyme Y435L
pelargonidin 3-O,5-O-di-beta-D-glucoside
-
-
peonidin-3-O-beta-D-glucoside
-
-
phenelzine sulfate
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal; mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
pirlindole
an MAO A specific reversible inhibitor
Proflavin
-
irreversible inhibitor
rhodiocyanoside A
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
rhodioloside B
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
rosiridin
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
salidroside
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
selegilline
-
specific inhibitor of isoform MAO-B
Sodium diethyldithiocarbamate
-
weak inhibition
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
non-selective; non-selective
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl][2-(phenylcarbonyl)phenyl]amino]-2-oxoethyl)carbamate
selective for MAO-B
tetrahydroharmine
-
identification by HPLC-ESI-mass spectrometry
trans,trans-farnesol
monoamine oxidase B
trans-2,4,5-trimethoxypropenylbenzene
IC50: 0.124 mM, monoamine oxidase A; IC50: 0.338 mM, monoamine oxidase B
trans-2-phenylcyclopropylamine
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
trans-trans-1,4-diphenyl-1,3-butadiene
-
-
tranylcypromine hydrochloride
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal; mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
triandrin
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
tyrosol
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
-
[(5E)-2,4-dioxo-5-(phenylimino)-1,3-thiazolidin-3-yl]acetonitrile
R598119
[(E)-1,3-dipropyl-7-methyl-8-(2-(3-thienyl)ethenyl)]xanthine
[(E)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[(E)-N-bis-(2-propynyl)-2-(phenyl)ethyidene]hydrazine
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[(Z)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
[4-(benzyloxy)phenoxy]hydrazine
0.1 mM, 43% inhibition
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
-
(E)-8-(3-chlorostyryl)caffeine
a specific reversible inhibitor of MAO-B
(E)-8-(3-chlorostyryl)caffeine
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(E)-8-(3-chlorostyryl)caffeine
-
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(E)-8-(3-chlorostyryl)caffeine
-
-
(E)-8-styrylcaffeine
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(E)-8-styrylcaffeine
-
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(R)-deprenyl
-
(R)-deprenyl
i.e. selegiline, a MAO-B inhibitor
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
-
-
1,4-diphenyl-1,3-butadiene
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
1,4-diphenyl-1,3-butadiene
-
-
1,4-diphenyl-2-butene
-
monoamine oxidase B
1,4-diphenyl-2-butene
-
inhibits by covalent binding to the flavin ring, reversible inhibitor of MAO-B
1,4-diphenyl-2-butene
monoamine oxidase B
1,4-diphenyl-2-butene
-
a component of polystyrene plasticware
1,4-diphenyl-2-butene
-
-
1,4-diphenyl-2-butene
monoamine oxidase B
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
-
-
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
-
-
2-(4'-butoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-butoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-butoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-butoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-ethoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-ethoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-ethoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-ethoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-methoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-methoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-methoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-methoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-propoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-propoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-propoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-propoxyphenyl)thiomorpholine oxalate
-
-
2-phenylcyclopropylamine
the inhibitor forms an adduct that allows reoxidation of the flavin on denaturation
2-phenylcyclopropylamine
moderate isoenzyme selectivity; moderate isoenzyme selectivity
2-phenylthiomorpholin-5-one
-
-
2-phenylthiomorpholin-5-one
-
-
2-phenylthiomorpholine oxalate
-
-
2-phenylthiomorpholine oxalate
-
-
4-Cyanophenol
-
weak inhibition
8-(3-chlorostyryl)caffeine
-
monoamine oxidase B
8-(3-chlorostyryl)caffeine
monoamine oxidase B
8-(3-chlorostyryl)caffeine
monoamine oxidase B
8-(3-chlorostyryl)caffeine
monoamine oxidase B
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
acridine
Neogale vison
-
derivatives, irrevrsible inhibition, sensitivity of isozymes, overview
acridine
-
derivatives, irrevrsible inhibition, sensitivity of isozymes, overview
Acridine orange
-
irreversible inhibitor
alpha-Naphthol
-
reversible by dialysis
amphetamine
-
-
amphetamine
-
a competitive inhibitor of MAO-A
beta-naphthol
-
reversible by dialysis
brofaromine
-
-
brofaromine
-
inhibitor of MAO-A
brofaromine
-
inhibits MAO-A reversibly
Caffeine
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
Caffeine
-
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
chlorgilin
-
i.e. N-[2,4-dichlorophenoxy]-propyl-N-methyl-2-propylamine
chlorgilin
-
i.e. N-[2,4-dichlorophenoxy]-propyl-N-methyl-2-propylamine
chlorgilin
-
i.e. N-[2,4-dichlorophenoxy]-propyl-N-methyl-2-propylamine
chlorgilin
-
i.e. N-[2,4-dichlorophenoxy]propyl-N-methyl-2-propynylamine
chlorgilin
-
i.e. N-[2,4-dichlorophenoxy]-propyl-N-methyl-2-propylamine
chlorgyline
-
-
chlorgyline
-
specific inhibitor of isoform MAO-A
Clorgyline
-
-
Clorgyline
complete inhibition at 0.01 mM
Clorgyline
-
irreversible inhibitor
Clorgyline
-
IC50: 0.00042 mM; IC50: 1.2 nM
Clorgyline
-
IC50: 0.000014 mM
Clorgyline
-
the irreversible MAO-A inhibitor shows anti-oncogenic and pro-differentiation effects on high grade prostate cancer cells, inhibition of MAO-A might restore differentiation and reverse the aggressive behavior of high grade prostate cancer cells, overview. The inhibitor has significant gene regulatory effects on the beta-catenin and ERBB2 pathways in vivo, overview
Clorgyline
an acetylenic inhibitor, addition of it results in the conversion of the oxidized flavin cofactors to their respective N(5) flavocyanine adducts
Clorgyline
inhibition of MAO A and MAO B
Clorgyline
-
inhibits both MAO-A and MAO-B
Clorgyline
-
inhibitor of MAO-A
Clorgyline
-
inhibits MAO-A irreversibly
Clorgyline
isoform MAO-A, 4.1% inhibition at 0.1 mM
Clorgyline
irreversible inhibitor of isoform MAO-A
Clorgyline
irreversible inhibitor of isoform MAO A
Clorgyline
-
selective inhibition of MAO-A
Clorgyline
complete inhibition at 0.01 mM
Clorgyline
-
MAO-A highly sensitive and MAO-B less sensitive to inhibition
Clorgyline
-
MAO-A highly sensitive and MAO-B less sensitive to inhibition; poor inhibition
Clorgyline
MAOA-specific irreversible inhibitor, used clinically as antidepressant. It foms a covalent bond with FAD
Clorgyline
monoamine oxidase A
Clorgyline
addition of the MAO-A inhibitor caused an increase in the maximal levels of extracellular serotonin achieved when challenged with 3,4-methylenedioxymethamphetamine
Clorgyline
the reversible and selective MAO-A inhibitor produces increases in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats
Clorgyline
addition of a 10fold molar excess of the acetylenic inhibitor clorgyline to rat MAO-A results in the formation of flavocyanine adduct
Clorgyline
MAO-A forms a N(5) flavocyanine adduct on inhibition by clorgyline, MAO A is blocked at an N-terminal threonyl residue
Clorgyline
irreversible inhibitor of isoform MAO-A
Clorgyline
-
MAO-A highly sensitive and MAO-B less sensitive to inhibition
D-amphetamine
-
-
D-amphetamine
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
D-amphetamine
competitive inhibition
D-amphetamine
a nonselective reversible MAO inhibitor, inhibits the MAO A S209E mutant with much lower affinity, 160fold and 20fold, respectively, than the wild-type enzyme
D-amphetamine
i.e. 1-phenyl-2-propanamine
D-amphetamine
reversible inhibitor; reversible inhibitor
deprenil
-
i.e. N-1-phenylisopropyl-N-methyl-2-propinylamine
deprenil
-
i.e. N-1-phenylisopropyl-N-methyl-2-propinylamine
deprenil
-
i.e. N-1-phenylisopropyl-N-methyl-2-propinylamine
deprenil
-
i.e. N-1-phenylisopropyl-N-methyl-2-propinylamine
Deprenyl
-
-
Deprenyl
-
i.e. N-1-phenylisopropyl-N-methyl-2-propynylamine
Deprenyl
complete inhibition at 0.01 mM
Deprenyl
-
inhibits the enzyme in vivo by 34-70% depending on the age, reversible by 4-chlorophenylalanine. Deprenyl administration decreases locomotion, altered vertical positioning and increased heart rate in larvae in vivo, 4-chlorophenylalanine normalizes serotonin levels and rescues the behavioral alteration
Deprenyl
-
IC50: 0.0023 mM; IC50: 3.3 mM
Deprenyl
-
IC50: 0.020 mM
Deprenyl
-
an acetylenic compound that forms covalent adducts with the N5 of the covalent FAD of MAO-B, pharmacologically inert as MAO-A inhibitor
Deprenyl
-
selective inhibition of MAO-B
Deprenyl
complete inhibition at 0.01 mM
Deprenyl
-
MAO-B sensitive
Harmaline
-
-
Harmaline
-
MAOI harmaline significantly reduces 5-MeO-DMT depletion and increases bufotenine formation in human hepatocytes
Harmaline
-
identification by HPLC-ESI-mass spectrometry. Potent reversible and strong inhibition of MAO-A, poor inhibition of MAO-B, from seeds
Harmaline
the ability of harmaline to modify the behavioral effects of 5-methoxy-N,N-dimethyltryptamine is mediated by the inhibition of MAOA. Serotonin2A receptors are responsible for the late hyperactivity induced by 5-methoxy-N,N-dimethyltryptamine in the presence of MAOA inhibitors
harman
-
-
harman
inhibition of MAO A
Harmane
-
-
Harmane
an MAO A specific reversible inhibitor
Harmane
-
reversible enzyme-specific inhibitor
harmine
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
harmine
-
identification by HPLC-ESI-mass spectrometry. Potent reversible and strong inhibition of MAO-A, poor inhibition of MAO-B, from seeds
Iproniazid
-
-
Iproniazid
-
nonselective inhibitor
iproniazid phosphate
-
-
Iproniazide
-
inhibits both MAO-A and MAO-B
Iproniazide
-
inhibitor of MAO-A and MAO-B
isatin
-
isatin
monoamine oxidase A; monoamine oxidase B
isatin
a nonselective reversible MAO inhibitor, inhibits the MAO A S209E mutant with much lower affinity, 160fold and 20fold, respectively, than the wild-type enzyme
isatin
-
inhibitor of MAO-B
isatin
-
non-specific reversible inhibitor
isatin
competitive inhibitor; competitive inhibitor
isatin
reversible inhibitor; reversible inhibitor
isocarboxazide
-
-
isocarboxazide
-
inhibitor of MAO-A and MAO-B
isocarboxazide
-
inhibits MAO-A and MAO-B irreversibly
KF-17837
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
KF-17837
-
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
KW-6002
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
KW-6002
-
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
L-deprenyl
-
L-deprenyl
inhibition of MAO A and MAO B
L-deprenyl
-
irreversible cerebral MAO-B inhibitor
ladostigil
-
ladostigil
-
nonselective inhibitor
lazabemide
-
-
lazabemide
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
lazabemide
-
inhibitor of MAO-B
lazabemide
-
inhibits MAO-B reversibly
lazabemide
-
selective inhibition of MAO-B
methylene blue
-
-
methylene blue
-
reversible enzyme-specific inhibitor
moclobemide
-
moclobemide
the MAO inhibitor is promising in the therapeutic management of post-traumatic stress disorder and panic disorder; the MAO inhibitor is promising in the therapeutic management of post-traumatic stress disorder and panic disorder
moclobemide
-
specific for MAO-A
moclobemide
-
inhibitor of MAO-A
moclobemide
-
inhibits MAO-A reversibly
moclobemide
-
specific for MAO-A
moclobemide
reversible inhibitor of isoform MAO-A
moclobemide
-
specific inhibitor of isoform MAO-A
moclobemide
reversible inhibitor of isoform MAO-A
mofegiline
mechanism-based irreversible, competitive inhibition versus substrate of MAO-B with a 1:1 molar stoichiometry, also competitively inhibits MAO-A. Effects on UV absorption spectra of flavin, and inhibitor-bound enzyme structure, overview
mofegiline
-
a vinyl fluoroamine
N,N'-(1R,2S)-cyclohexane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-(1R,2S)-cyclohexane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-1,2-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-1,2-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-1,4-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-1,4-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-butane-1,4-diylbis(2-oxo-2H-chromene-3-carboxamide)
potent inhibitor of MAO-A with high selectivity towards MAO-B; potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-butane-1,4-diylbis(2-oxo-2H-chromene-3-carboxamide)
potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-butane-1,4-diylbis(7-methoxy-2-oxo-2H-chromene-3-carboxamide)
-
N,N'-butane-1,4-diylbis(7-methoxy-2-oxo-2H-chromene-3-carboxamide)
-
N,N'-ethane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-ethane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-hexane-1,6-diylbis(2-oxo-2H-chromene-3-carboxamide)
potent inhibitor of MAO-A with high selectivity towards MAO-B; potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-hexane-1,6-diylbis(2-oxo-2H-chromene-3-carboxamide)
potent inhibitor of MAO-A with high selectivity towards MAO-B
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
i.e. ParSL-1, a TEMPO-conjugated pargyline analogue; i.e. ParSL-1, a TEMPO-conjugated pargyline analogue
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
N-(2-aminoethyl)-p-chlorobenzamide
-
inhibits by covalent binding to the flavin ring
N-(2-aminoethyl)-p-chlorobenzamide
-
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441; NTZ-1441
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441; NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442; NTZ-1442
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442; NTZ-1442
N-phenyl-1H-indazole-5-carboxamide
-
N-phenyl-1H-indazole-5-carboxamide
-
norharman
-
competitive reversible and potent inhibitor
norharman
inhibition of MAO A; inhibition of MAO B
Pargyline
-
-
Pargyline
-
MAO-B sensitive
Pargyline
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
Pargyline
construction of three TEMPO-conjugated pargyline analogues ParSL-1, ParSL-2, and ParSL-3, which differ in flexibility and substituent positions of the linkers connecting the TEMPO group to the pargyline phenyl ring. The variations in conformational flexibility and substituent position have profound effects in tuning the specificities of these analogues toward the MAO isoforms, inhibitor synthesis, overview; construction of three TEMPO-conjugated pargyline analogues ParSL-1, ParSL-2, and ParSL-3, which differ in flexibility and substituent positions of the linkers connecting the TEMPO group to the pargyline phenyl ring. The variations in conformational flexibility and substituent position have profound effects in tuning the specificities of these analogues toward the MAO isoforms, inhibitor synthesis, overview
Pargyline
-
inhibitor of MAO-A and MAO-B
Pargyline
-
inhibits MAO-A and MAO-B irreversibly
Pargyline
-
MAO-B sensitive
Pargyline
-
irreversible inhibitor
Pargyline
monoamine oxidase B
Pargyline
the irreversible and non-selective MAO inhibitor produces increases in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats
Pargyline
-
irreversible inhibitor. Pargyline + semicarbazide-induced reduction of fat deposition results from decreased food intake and from impaired MAO and SSAO-dependent lipogenic and antilipolytic actions of endogenous or alimentary amines
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview; a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview; a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
Phenelzine
-
-
Phenelzine
concentration-dependent inhibition
Phenelzine
-
the nonselective irreversible inhibitor of monoamine oxidase causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition
Phenelzine
weak inhibition of MAO-A
pheniprazine
i.e. (1-methyl-2-phenylethyl)hydrazine. Mechanism-based MAO inhibitor
pheniprazine
i.e. (1-methyl-2-phenylethyl)hydrazine. As a reversible inhibitor it is selective towards rat liver MAO-A but the rate of irreversible inhibition of that enzyme is considerably slower; i.e. (1-methyl-2-phenylethyl)hydrazine. Mechanism-based MAO inhibitor
phentermine
-
phentermine
binding to the S209E mutant is reduced by 13fold compatred to the wild-type MAO A
phentermine
i.e. 2-methyl-1-phenyl-2-propanamine; i.e. 2-methyl-1-phenyl-2-propanamine
phentermine
reversible inhibitor; reversible inhibitor
Phenylethylhydrazine
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview; the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
phenylhydrazine
-
-
phenylhydrazine
weak binding; weak binding
pirlindole mesylate
-
-
pirlindole mesylate
-
reversible enzyme-specific inhibitor
pyronine G
-
irreversible inhibitor
R-(-)-deprenyl
-
inhibits both MAO-A and MAO-B
R-(-)-deprenyl
-
inhibitor of MAO-B
R-(-)-deprenyl
-
inhibits MAO-B irreversibly
R-(-)-deprenyl
-
highly active with MAO-B
rasagiline
-
rasagiline
i.e. N-propargyl-1-R-aminoindan. Irreversible MAO B inhibitor. Rasagiline is initiated at 1 mg once-daily dosage as monotherapy in early Parkinsons disease patients and at 0.5-1 mg once-daily as adjunctive to levodopa in advanced Parkinsons disease patients. Rasagiline treatment is not associated with cheese effect and up to 20 mg per day is well tolerated. In Parkinsons disease patients with hepatic impairment, rasagiline dosage should be carefully adjusted. Rasagiline should not be administered with other MAO inhibitors and coadministration with certain antidepressants and opioids should be avoided. This drug provides an additional tool for Parkinsons disease therapy improvement in motor performance
rasagiline
-
an acetylenic compound that forms covalent adducts with the N5 of the covalent FAD of MAO-B, pharmacologically inert as MAO-A inhibitor. A rasagiline analog methylated on the amino moiety of the propargyline chain connecting the inhibitor to the flavin loses this characteristic specificity for MAO-B
rasagiline
-
inhibitor of MAO-B
rasagiline
-
inhibits MAO-B irreversibly
rasagiline
irreversible inhibitor of isoform MAO-B
rasagiline
irreversible inhibitor of isoform MAO-B
rasagiline
specific MAO-B inhibitor
Ro 41-1049
-
-
safinamide
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
safinamide
-
a very specific MAO B non-covalent inhibitor, may function effectively as a neuroprotectant
safinamide
reversible inhibitor of isoform MAO-B
safinamide
reversible inhibitor of isoform MAO-B
selegiline
-
selegiline
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
selegiline
the MAO B inhibitor is efficacious in the therapeutic management of Parkinson's disease
selegiline
-
an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression
selegiline
irreversible inhibitor of isoform MAO-B
selegiline
irreversible inhibitor of isoform MAO B
selegiline
-
irreversible cerebral MAO-B inhibitor
selegiline
administration of the irreversible and selective MAO-B inhibitor selegiline does not produce any increase in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats, compared with the saline control
selegiline
irreversible inhibitor of isoform MAO-B
selegiline
specific MAO-B inhibitor
Semicarbazide
-
-
Semicarbazide
-
complete inhibition at 0.01 mM
takrin
-
irreversible inhibitor
tetrindole
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
tetrindole
an MAO A specific reversible inhibitor
tetrindole mesylate
-
-
tetrindole mesylate
-
reversible enzyme-specific inhibitor
toloxatone
-
-
toloxatone
-
inhibitor of MAO-A
toloxatone
-
inhibits MAO-A reversibly
trans-2-phenylcyclopropylamine
-
inhibits by covalent binding to the flavin ring
trans-2-phenylcyclopropylamine
2-PCPA; 2-PCPA
tranylcypromine
-
-
tranylcypromine
inhibition of MAO-B
tranylcypromine
inactivation of recombinant human MAO-B with tranylcypromine results in the formation of a high affinity I2 site on the enzyme, measured as an increase in binding of 2-(2-benzofuranyl)-2-imidazoline. Inhibition by tranylcypromine results in displacement of Q206 and closure of the I199 gate
tranylcypromine
-
nonselective inhibitor
ZnSO4
-
1 mM, 10% inhibition, monoamine oxidase B; 1 mM, 85% inhibition with serotonin as substrate, competitive, reversible, monoamine oxidase A
ZnSO4
-
1 mM, about 20% inhibition, monoamine oxidase A
ZnSO4
-
1 mM, about 20% inhibition, monoamine oxidase A
[(E)-1,3-dipropyl-7-methyl-8-(2-(3-thienyl)ethenyl)]xanthine
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
[(E)-1,3-dipropyl-7-methyl-8-(2-(3-thienyl)ethenyl)]xanthine
-
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
the complex 1 is a potent MAO-B inhibitor
-
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
the complex 1 is a potent MAO-B inhibitor
-
additional information
-
enzyme activity is not inhibited by pargyline, clorgyline, semicarbazide, or sodium diethyldithiocarbamate
-
additional information
no inhibition of monoamine oxidase B: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine or 1,4-diphenyl-2-butene
-
additional information
-
no inhibition of monoamine oxidase B: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine or 1,4-diphenyl-2-butene
-
additional information
-
comparison of two regions in the polypeptide sequence of C-MAO determining possible substrate/inhibitor preferences of mammalian MAO-A and MAO-B show both 79.5% homologies, overview
-
additional information
-
not inhibited by D-amphetamine, farnesol, safinamide, 1,4-diphenyl-1,3-butadiene, and 1,4-diphenyl-2-butene
-
additional information
-
cigarette smoke is a potent inhibitor of MAO-A. Inhibition is partly reversible, competitive. beta-Carboline alkaloids from cigarette smoke acting as potent reversible inhibitors may contribute to the MAO reduced activity produced by tobacco smoke in smokers; cigarette smoke is a potent inhibitor of MAO-B. Inhibition is partly reversible, competitive. Veta-carboline alkaloids from cigarette smoke acting as potent reversible inhibitors may contribute to the MAO reduced activity produced by tobacco smoke in smokers
-
additional information
-
no inhibition by Mesobuthus gibbosus venom peptide
-
additional information
no inhibition by 4-hydroxy-3-methoxyophenylethyl alcohol, ethyl-4-hydroxy-3-methoxyphenylacetate, metanephrine, 3,4-dimethoxy-5-hydroxybenzaldehyde and 3-methoxyphenol
-
additional information
no inhibition by 4-hydroxy-3-methoxyophenylethyl alcohol, ethyl-4-hydroxy-3-methoxyphenylacetate, metanephrine, 3,4-dimethoxy-5-hydroxybenzaldehyde and 3-methoxyphenol
-
additional information
recombinant enzyme obtained from a Baculovirus expression system is validated as convenient enzyme source for MAO B inhibitor screening
-
additional information
-
recombinant enzyme obtained from a Baculovirus expression system is validated as convenient enzyme source for MAO B inhibitor screening
-
additional information
both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes; both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes
-
additional information
both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes; both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes
-
additional information
no inhibition of monoamine oxidase A: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene
-
additional information
no inhibition of monoamine oxidase A: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene
-
additional information
-
no inhibition of monoamine oxidase A: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene
-
additional information
coffee contains compounds acting as reversible and competitive inhibitors for MAO A; coffee contains compounds acting as reversible and competitive inhibitors for MAO B
-
additional information
coffee contains compounds acting as reversible and competitive inhibitors for MAO A; coffee contains compounds acting as reversible and competitive inhibitors for MAO B
-
additional information
-
coffee contains compounds acting as reversible and competitive inhibitors for MAO A; coffee contains compounds acting as reversible and competitive inhibitors for MAO B
-
additional information
evaluation of the application of UCSF DOCK to screen for inhibitors of MAO-B
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs; the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs; the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
-
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs; the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
no inhibition: 1,4-diphenyl-2-butene and chlorostyrylcaffeine
-
additional information
-
no inhibition: 1,4-diphenyl-2-butene and chlorostyrylcaffeine
-
additional information
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7; synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7; synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
-
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7; synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. No inhibition of MAO-A by (E)-8-(3-chlorostyryl)caffeine; synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. The (E)-5-styrylisatin analogue binds more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity
-
additional information
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. No inhibition of MAO-A by (E)-8-(3-chlorostyryl)caffeine; synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. The (E)-5-styrylisatin analogue binds more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity
-
additional information
-
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. No inhibition of MAO-A by (E)-8-(3-chlorostyryl)caffeine; synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. The (E)-5-styrylisatin analogue binds more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity
-
additional information
successful SRY knockdown inhibits MAO A catalytic activity by 45%
-
additional information
-
successful SRY knockdown inhibits MAO A catalytic activity by 45%
-
additional information
Rhodiola rosea roots have potent antidepressant activity by inhibiting MAO A and may also find application in the control of senile dementia by their inhibition of MAO B, no inhibition of both isozymes by rosavin, rosarin, and rosin
-
additional information
inhibitors of MAO-B can be adjunctive drugs to levodopa. Neuroprotective and anti-Parkinsonian effects of A2A receptor antogonistic drugs, overview
-
additional information
-
inhibitor binding affects the active site structures of MAO-A and MAO-B, overview
-
additional information
-
development and synthesis of benzylidene-prop-2-ynyl-amines analogues as monoamine oxidase inhibitors, ligand docking and molecular modelling, overview. In the active center, Ile199 is the gate residue, and two hydrophobic areas of the enzyme are implicated in the most stable binding mode. Hydrophobic pocket is delimited by Ile198, Ile199, Gln206, Phe343, and aromatic cage contains FAD, Tyr398 and Tyr435
-
additional information
-
evaluation of chromone carboxylic acids as enzyme inhibitors, only chromone-3-carboxylic acid is a potent MAO-B inhibitor, with a high degree of selectivity for MAO-B compared to MAO-A, no inhibition by 4-oxo-4H-chromene-2-carboxylic acid at 0.1 mM, molecular docking, overview
-
additional information
-
inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues, quantitative structure-activity relationship studies, overview
-
additional information
-
2-arylthiomorpholine and 2-arylthiomorpholin-5-one derivatives, designed as rigid and/or non-basic phenylethylamine analogues, as monoamine oxidase inhibitors, molecular docking using crystal structures of human MAO-B, PDB ID 1S3E, and MAO-A, PDB ID 2BXS, overview
-
additional information
-
cycloalkylidenhydrazothiazole derivative inhibitors derived from N1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole, molecular modeling, overview. No inhibition by 13, 42, and 44
-
additional information
-
synthesis and molecular modeling of selective monoamine oxidase inhibitors from a 2-thiazolylhydrazyne scaffold, structure-activity relationships, overview. No or poor activity against MAO-A with 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine, and 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine, and against MAO-B with 5, 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine, 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine, 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine, and 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)-hydrazine
-
additional information
-
4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains as enzyme inhibitors. Design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis, and antitumor activities against human lung cancer A-549 and human prostate cancer PC-3 cell lines, overview
-
additional information
design and synthesis of a series of indole and benzofuran derivatives, and evaluation as reversible inhibitors of the two MAO isozymes MAO-A and MAO-B, most compounds are selective MAO-B inhibitors, ligand docking study, overview
-
additional information
-
synthesis of 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives and evaluation of their monoamine oxidase inhibitory activity, ligand docking and mechanism of inhibition, molecular modelling, overview. Comparison with 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole and 2-thiazolyl hydrazones, overview. No or poor inhibition of MAO-A by all compounds tested, no inhibition of MAO-B by compounds 1-thiocarbamoyl-3-(4-fluorophenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(3-methylphenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(2-methylphenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(3-methoxyphenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(2,4-dichlorophenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(thiophen-2-yl)-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-(2-methylphenyl)-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-(thiophen-2-yl)-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4-methyl-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(4-fluorophenyl)-4-methyl-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4-methyl-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(4-methylphenyl)-4-methyl-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-phenyl-4-methyl-4,5-dihydropyrazole, 1-thiocarbamoyl-3-phenyl-4-methyl-4,5-dihydropyrazole, and 1-thiocarbamoyl-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
-
additional information
-
enzyme inhibition by beta-carboline alkaloids from seeds and roots of Peganum harmala, low levels in stems and leaves, and absence in flowers, overview. Seed extracts are potent reversible and competitive inhibitors of human MAO-A with an IC50 of 0.027 mg/L whereas root extracts strongly inhibit MAO-A with an IC50 of 0.159 mg/L. In contrast, they are poor inhibitors of MAO-B. Inhibition of MAO-A by seed extracts is quantitatively attributed to harmaline and harmine whereas inhibition by root extracts came from harmine with no additional interferences
-
additional information
-
nitroindazole isomers are good hydroxyl radical scavengers and inhibhit MPTP neurotoxin oxidation by MAO. Compounds 4, 5, 6, 7, 8, 9, 10, and 11 are poor inhibitors
-
additional information
-
extracts from Fructus crataegi and Radix polygoni multiflori plants show MAO-B inhibition by 56% and 69%, respectively. The extracts of several other plants are not inhibitory for MAO-B, overview
-
additional information
-
MAO-B and MAO-A, clinical study, in vivo inhibitory activity, detailed overview
-
additional information
-
synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins, molecular modeling, overview
-
additional information
-
MAO-A is not inhibited by most of the chalcone compounds tested for MAO inhibitory activity, no inhibition of MAO-B by 5c, 5d, and 5f, overview
-
additional information
-
25 anthocyanidins, anthocyanidin-3-glycosides, anthocyanidin-3,5-diglucosides, proanthocyanidins, and phenolic metabolites are examined as MAO inhibitors, overview
-
additional information
-
isoform MAO B is not inhibited by pirlindole
-
additional information
no inhibition by catechin and cyanidin; no inhibitipon by catechin and cyanidin
-
additional information
no inhibition by catechin and cyanidin; no inhibitipon by catechin and cyanidin
-
additional information
-
no inhibition by catechin and cyanidin; no inhibitipon by catechin and cyanidin
-
additional information
-
the enzyme is not suppressed by 10 mM semicarbazide
-
additional information
-
insensitive to semicarbazide
-
additional information
-
the inhibitors show no neuroprotective effects in female scrapie-infected hamsters, overview
-
additional information
inhibitory potencies of methylpiperate derivatives from Piper longum, no inhibition by isolated piperlonguminine; inhibitory potencies of methylpiperate derivatives from Piper longum, no inhibition by isolated piperlonguminine
-
additional information
inhibitory potencies of methylpiperate derivatives from Piper longum, no inhibition by isolated piperlonguminine; inhibitory potencies of methylpiperate derivatives from Piper longum, no inhibition by isolated piperlonguminine
-
additional information
-
inhibitory potencies of methylpiperate derivatives from Piper longum, no inhibition by isolated piperlonguminine; inhibitory potencies of methylpiperate derivatives from Piper longum, no inhibition by isolated piperlonguminine
-
additional information
-
inhibitors of MAO-B can be adjunctive drugs to levodopa. Neuroprotective and anti-Parkinsonian effects of A2A receptor antogonistic drugs, overview
-
additional information
-
hardly inhibited by 1 mM o-phenanthroline (4%), pargyline (2%) and clorgyline (1%)
-
additional information
Neogale vison
-
the enzyme is not inhibited by semicarbazide
-
additional information
-
no inhibition of monoamine oxidase B: isatin, trans,trans-farnesol, 8-(3-chlorostyryl)caffeine or 1,4-diphenyl-2-butene
-
additional information
-
inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues, quantitative structure-activity relationship studies, overview
-
additional information
-
potent reversible pteridine-2,4-dione analogue inhibitor development and synthesis, molecular modelling of MAO-B ligand binding, overview
-
additional information
-
not inhibited by 100 mM semicarbazide
-
additional information
-
insensitive to semicarbazide
-
additional information
-
not inhibited by 100 mM semicarbazide
-
additional information
-
inhibitors with a substitution at the 5-position in 2-[N-(2-propynyl) aminomethyl]-1-methyl indole
-
additional information
-
overview: selective inhibitors of form A and B
-
additional information
-
no inhibition by Mesobuthus gibbosus venom peptide
-
additional information
alkylamino derivatives of 4-aminomethylpyridine, substrate-like, reversible inhibitors
-
additional information
alkylamino derivatives of 4-aminomethylpyridine, substrate-like, reversible inhibitors
-
additional information
no inhibition: 1-thiocarbamoyl-3-phenyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole, thiocarbamoyl-3-phenyl-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs; the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs; the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
monoamine oxidase-B inhibitors and antiinflammatory agents might be effective in treating Alzheimers disease
-
additional information
monoamine oxidase-B inhibitors and antiinflammatory agents might be effective in treating Alzheimers disease
-
additional information
no inhibition: 1,4-diphenyl-2-butene and chlorostyrylcaffeine
-
additional information
-
SSAO inhibition is not sufficient to impair fat deposition. Combined MAO and SSAO inhibition limits adiposity in non-obese as well as in obese rats
-
additional information
naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-A and MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety; naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety. No inhibition of MAOB by N-4-methoxybenzyl-(4-methylthioamphetamine) hydrochloride, N-4-butoxybenzyl-(4-methylthioamphetamine) hydrochloride, and N-4-benzyloxybenzyl-(4-methylthioamphetamine) hydrochloride
-
additional information
naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-A and MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety; naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety. No inhibition of MAOB by N-4-methoxybenzyl-(4-methylthioamphetamine) hydrochloride, N-4-butoxybenzyl-(4-methylthioamphetamine) hydrochloride, and N-4-benzyloxybenzyl-(4-methylthioamphetamine) hydrochloride
-
additional information
no inhibhition of MAO-A by selegiline; no inhibition of MAO-B by clorgyline
-
additional information
no inhibhition of MAO-A by selegiline; no inhibition of MAO-B by clorgyline
-
additional information
-
no inhibhition of MAO-A by selegiline; no inhibition of MAO-B by clorgyline
-
additional information
-
no inhibition of MAO-A by farnesol, chlorostyrylcaffeine, and 1,4-diphenyl-2-butene; not inhibited by farnesol, chlorostyrylcaffeine and 1,4-diphenyl-2-butene
-
additional information
no inhibition of MAO-A by farnesol, chlorostyrylcaffeine, and 1,4-diphenyl-2-butene; not inhibited by farnesol, chlorostyrylcaffeine and 1,4-diphenyl-2-butene
-
additional information
-
the enzyme is not inhibited by semicarbazide
-
additional information
-
inhibitor binding affects the active site structures of MAO A and MAO B, overview
-
additional information
-
synthesis and molecular modeling of some hexahydroindazole derivatives as potent monoamine oxidase inhibitors, overview
-
additional information
-
2-arylthiomorpholine and 2-arylthiomorpholin-5-one derivatives, designed as rigid and/or non-basic phenylethylamine analogues, as monoamine oxidase inhibitors, overview
-
additional information
molecular docking of MAO-A and MAO-B, overview
-
additional information
-
design, synthesis, and evaluation of selective MAO-B inhibitors with favorable physicochemical and pharmacokinetic profiles, 7-[(m-halogeno)benzyloxy]coumarins bearing properly selected polar substituents at position 4, overview
-
additional information
-
isoform MAO-B is not inhibited by (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate, (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate, (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate, (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate, (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate, (3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate, (3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate, (3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate, moclobemide, 3-oxo-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate, and 7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
-
additional information
3-phenyl-4-(phenyltelluro) isoquinoline does not inhibit 50% of the isoform MAO-B activity up to concentration of 0.1 mM
-